KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash & Equivalents (2016 - 2025)

Novavax (NVAX) has 16 years of Cash & Equivalents data on record, last reported at $240.6 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 54.62% year-over-year to $240.6 million; the TTM value through Dec 2025 reached $240.6 million, down 54.62%, while the annual FY2025 figure was $240.6 million, 54.62% down from the prior year.
  • Cash & Equivalents reached $240.6 million in Q4 2025 per NVAX's latest filing, down from $268.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $2.0 billion in Q1 2021 and bottomed at $8.2 million in Q3 2021.
  • Average Cash & Equivalents over 5 years is $597.8 million, with a median of $493.2 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 15564.6% in 2022, then crashed 99.19% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $11.5 million in 2021, then surged by 11535.19% to $1.3 billion in 2022, then plummeted by 57.48% to $568.5 million in 2023, then fell by 6.73% to $530.2 million in 2024, then plummeted by 54.62% to $240.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $240.6 million in Q4 2025, $268.0 million in Q3 2025, and $253.7 million in Q2 2025.